sitagliptin , 97% , 486460-32-6
CAS NO.:486460-32-6
Empirical Formula: C16H15F6N5O
Molecular Weight: 407.31
MDL number: MFCD09838015
EINECS: 690-730-1
Pack Size | Price | Stock | Quantity |
100MG | RMB111.20 | In Stock |
|
1G | RMB194.40 | In Stock |
|
5g | RMB594.40 | In Stock |
|
25g | RMB1690.40 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 114.1-115.7 °C |
Boiling point: | 529.9±60.0 °C(Predicted) |
Density | 1.61±0.1 g/cm3(Predicted) |
storage temp. | Store at -20°C |
solubility | DMSO : ≥ 50 mg/mL (122.76 mM) |
pka | 7.20±0.10(Predicted) |
form | Solid |
color | White to off-white |
InChI | InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
InChIKey | MFFMDFFZMYYVKS-SECBINFHSA-N |
SMILES | C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F |
CAS DataBase Reference | 486460-32-6(CAS DataBase Reference) |
EPA Substance Registry System | 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (486460-32-6) |
Description and Uses
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.
Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-?diabetes, impaired glucose tolerance, hepatitis, and?/or inflammatory liver disease.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H302-H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
Hazardous Substances Data | 486460-32-6(Hazardous Substances Data) |